Caladrius Biosciences to Participate at the Upcoming September Conferences
September 05 2019 - 4:05PM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a late-stage therapeutics development biopharmaceutical
company pioneering advancements of cell therapies in select
cardiovascular and autoimmune diseases, announced today that
management will participate in the following conferences in
September:
21st Annual Global Investment Conference,
Sponsored by H.C. Wainwright |
|
|
|
Date & Time: |
|
Thursday, September 12, 2019 at 12:05 p.m. (EDT) |
Presenter: |
|
David J. Mazzo, Ph.D. |
Venue: |
|
Lotte New York Palace Hotel in New York, NY |
Live Webcast: |
|
wsw.com/webcast/hcw5/clbs/ |
|
|
|
Texas Heart Institute: Cardiology Grand
Rounds |
|
|
|
Title: |
|
The Microcirculation: Center of the Cardiovascular Regenerative
Medicine Universe |
Date & Time: |
|
Friday, September 13, 2019 at 12:00 p.m. (CDT) |
Presenter: |
|
Douglas W. Losordo, MD, FACC, FAHA Executive Vice President,
Global Head of Research and Development, Chief Medical Officer |
Venue: |
|
Texas Heart Institute Denton A. Cooley Auditorium |
Live Webcast: |
|
Texasheart.org/grandrounds |
|
|
|
Investing for Cures 2019 |
|
|
|
Date & Time: |
|
Thursday, September 19, 2019 at 9:55 a.m. (EDT) |
Presenter: |
|
David J. Mazzo, Ph.D. |
Venue: |
|
Lotte New York Palace Hotel in New York, NY |
|
|
|
Cincinnati College of Pharmacy Seminar
Series |
|
|
|
Title: |
|
The CD34 Cell: Experimental Evidence in Animals and Humans for
Angiogenesis and Ischemic Repair |
Date & Time: |
|
Thursday, September 19, 2019 at 5:00 p.m. (EDT) |
Presenter: |
|
William K. Sietsema, Ph.D., Vice President, Global Regulatory
Affairs |
Venue: |
|
University of Cincinnati College of Pharmacy |
About Caladrius BiosciencesCaladrius is a
late-stage therapeutics development biopharmaceutical company
pioneering advancements of cell therapies for select cardiovascular
and autoimmune diseases. Our leadership team collectively has
decades of biopharmaceutical development experience and
world-recognized scientific achievement in the fields of
cardiovascular and autoimmune disease, among other areas. Our
current product candidates include three developmental treatments
for cardiovascular diseases based on our CD34+ cell therapy
platform: CLBS12, recipient of a SAKIGAKE designation in Japan and
advanced therapy medicinal product classification (ATMP) in Europe,
eligible for early conditional approval for the treatment of
critical limb ischemia in Japan based on an ongoing clinical trial;
CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial
in the U.S.A. for the treatment of coronary microvascular
dysfunction; and CLBS14, recipient of a RMAT designation in the
U.S.A. and for which we are in preparation to commence a Phase 3
clinical trial in no option refractory disabling angina. For more
information on the company, please
visit www.caladrius.com.
Contact:
Investors: Caladrius Biosciences, Inc. John Menditto Vice
President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2023 to Apr 2024